Nonalcoholic Steatohepatitis (NASH) Clinical Trial
Official title:
A Phase 2, Randomized Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis (NASH)
This is a Phase 2, randomized, double-blind, placebo controlled, three arm study in adult men with biopsy confirmed NASH. The study is aimed at evaluating efficacy and tolerability of LPCN 1144 in adult men with NASH.
This is a Phase 2, randomized, double-blind, placebo controlled, three arm study in adult men with biopsy confirmed NASH. The study is aimed at evaluating efficacy and tolerability of LPCN 1144 in adult men with NASH. The study will be conducted across multiple centers in the United States. Approximately 75 subjects will be randomized in 1:1:1 ratio to receive one of the following treatments: - Treatment A: Oral LPCN 1144 Formulation A - Treatment B: Oral LPCN 1144 Formulation B - Treatment C: Oral matching placebo Subjects will undergo a screening period to determine study eligibility. As a part of screening, liver biopsies will be performed for subjects who have not had a liver biopsy within 6 months of Day 1, and fat fraction will be measured by magnetic resonance imaging derived proton density fat fraction (MRI-PDFF) in all subjects. Adult male subjects with histologic evidence of NASH will be enrolled into the study. Eligible subjects will be randomized to one of the three treatment arms. The treatment phase will be for a duration of 36-weeks with assessments of liver biopsies, hepatic fat fraction, liver enzymes, lipid levels and other safety parameters. Safety and tolerability will be assessed throughout the study. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04880031 -
A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH)
|
Phase 2 | |
Suspended |
NCT04104321 -
A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)
|
Phase 3 | |
Completed |
NCT02891408 -
Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function
|
Phase 1 | |
Completed |
NCT04546984 -
Multiple Dose Safety, Tolerability, PK,PD and Food Effect Study of HEC96719 in Healthy Adult Subjects
|
Phase 1 | |
Recruiting |
NCT05842512 -
Study of ADI-PEG 20 Versus Placebo in Subjects With NASH
|
Phase 2 | |
Completed |
NCT02854605 -
Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)
|
Phase 2 | |
Recruiting |
NCT06108219 -
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
|
Phase 2 | |
Recruiting |
NCT03572465 -
Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis
|
||
Active, not recruiting |
NCT05402371 -
A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis
|
Phase 2 | |
Terminated |
NCT03823703 -
Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)
|
Phase 2 | |
Recruiting |
NCT05117489 -
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
|
Phase 1 | |
Completed |
NCT04165343 -
Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on EXPLORER
|
||
Recruiting |
NCT04913090 -
A Phase I Clinical Trial of XZP-5610 Tablets in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06024408 -
A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor
|
Phase 1 | |
Terminated |
NCT04004325 -
A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis
|
Phase 1/Phase 2 | |
Completed |
NCT06037577 -
Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects
|
Phase 1 | |
Active, not recruiting |
NCT05320146 -
A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
|
||
Completed |
NCT01265498 -
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)
|
Phase 2 | |
Terminated |
NCT00845845 -
Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
|
Phase 2 | |
Terminated |
NCT04267393 -
Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)
|
Phase 2 |